

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: markspencer

Timestamp: [year=2009; month=7; day=2; hr=14; min=4; sec=23; ms=495; ]

=====

Application No: 10593484

Version No: 2.0

Input Set:

Output Set:

Started: 2009-06-23 17:12:43.607

Finished: 2009-06-23 17:12:44.734

Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 127 ms

Total Warnings: 14

Total Errors: 0

No. of SeqIDs Defined: 14

Actual SeqID Count: 14

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)

# SEQUENCE LISTING

<110> DSM IP ASSETS B.V.  
 Jochen KLOCK  
 Philippe Emmanuel MAILLAN  
 Juergen H. VOLLHARDT  
 Raphael BEUMER

<120> Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use

<130> 4804-3

<140> 10593484

<141> 2009-06-23

<150> PCT/EP2005/003116

<151> 2005-03-23

<150> EP 04007282.9

<151> 2004-03-26

<160> 14

<170> MS Word

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 1

Arg Gly Asp Ser

1

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 2

Gly Gln Pro Arg

1

<210> 3

<211> 4

<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 3

Phe Gly Ala Leu  
1

<210> 4  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa is PhBu

<400> 4

Xaa Gly Gln Pro Arg  
1 5

<210> 5  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 5

Arg Pro Phe Phe  
1

<210> 6  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 6

Tyr Lys Pro Arg

1

<210> 7  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 7

Gly Gln Pro Arg  
1

<210> 8  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 8

Phe Tyr Arg Pro Arg  
1 5

<210> 9  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 9

Ala Arg Asp Pro Arg  
1 5

<210> 10  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 10

Asn Ser Leu Asp Phe  
1 5

<210> 11  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 11

Lys Thr Thr Lys Ser  
1 5

<210> 12  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 12

Leu Arg Gly Ile Leu  
1 5

<210> 13  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 13

Lys Gly Ile Leu  
1

<210> 14  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<400> 14

Lys Leu Asp Ala Pro Thr  
1 5

